Sort
10,766 grants matching “checkpoint inhibitor”
Understanding IDH mutant gliomas
$565,046Jing Wu · Division Of Basic Sciences - Nci · ZIA · FY2020 · CA
The role of Galectin-1 in shaping the immune suppressive landscape in head and neck cancer
$564,874Quynh-Thu X Le · Stanford University · R01 · FY2024 · DE
Engineered Nanoformulation for Immune-modulation in Cancer
$564,843Rajagopal Ramesh · University Of Oklahoma Hlth Sciences Ctr · R01 · FY2025 · CA
Defining the Pathogenesis and Prognosis of Human Acute Interstitial Nephritis
$564,483Lloyd G Cantley · Yale University · R01 · FY2020 · DK
Constrained Fetal Hematopoiesis and Clonal Restriction in Fanconi Anemia
$564,423Peter Kurre · Children'S Hosp Of Philadelphia · R01 · FY2022 · HL
Targeting the fibroblast-immune cell crosstalk to relieve immune suppression in the pancreatic cancer microenvironment
$564,229Marina Pasca Di Magliano · University Of Michigan At Ann Arbor · R01 · FY2022 · CA
Towards Translation of MU-CN29: New Therapeutic Nanoparticle for Drug-Resistant NSCLC
$563,952Raghuraman Kannan · University Of Missouri-Columbia · R01 · FY2025 · CA
Targeting the mutant promoter of Telomerase Reverse Transcriptase (TERT)
$563,904Dan Theodorescu · Cedars-Sinai Medical Center · R01 · FY2024 · CA
Targeting STAT3 for the Treatment of CDK4/6 Inhibitor Resistant Advanced Estrogen Receptor Positive Breast Cancer Patients
$563,903Khandan Keyomarsi · University Of Tx Md Anderson Can Ctr · R01 · FY2024 · CA
A new mouse model for studying the pathogenesis and immunobiology of intrahepatic cholangiocarcinoma and improving its immunotherapy
$563,902Michael Karin · University Of California, San Diego · R01 · FY2023 · CA
Conserved Element DNA Vaccine
$563,898Barbara Felber · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA
Advancing immunotherapy through cross species studies of immune cell responses and immune checkpoint inhibitor effects in dogs and humans with invasive urinary bladder cancer
$563,811Deborah W Knapp · Purdue University · U01 · FY2022 · CA
Cutaneous T cell lymphoma: a paradigm for dissecting susceptibility and resistance to checkpoint inhibition therapy
$563,656Christiane Querfeld · Beckman Research Institute/City Of Hope · R01 · FY2022 · CA
Cutaneous T cell lymphoma: a paradigm for dissecting susceptibility and resistance to checkpoint inhibition therapy
$563,656Christiane Querfeld · Beckman Research Institute/City Of Hope · R01 · FY2021 · CA
Targeting S1P-ACC Axis to Overcome MDSC Suppression
$563,233Shikhar Mehrotra · Medical University Of South Carolina · R01 · FY2025 · CA
Dissecting the immunomodulatory effects of NK cells on immune responses to cancer
$563,228Kevin C Barry · Fred Hutchinson Cancer Center · R01 · FY2025 · CA
Expanding the cancer paralog genetic interaction map to enable precision oncology
$563,170Alice Berger · Fred Hutchinson Cancer Center · R01 · FY2024 · CA
Molecular Mechanisms and inhibition of Protein Acetyltransferases
$563,160Ronen Marmorstein · University Of Pennsylvania · R35 · FY2020 · GM
Sulindac sensitizes colorectal cancer to anti-PD-L1 therapy
$563,009Yaguang Xi · University Of Georgia · R01 · FY2023 · CA
Project 3: Tools for Capturing Immune Cell/Cancer Cell Interactions in Cancer Immunotherapies and Combination Immunotherapies
$562,890James R. Heath · Institute For Systems Biology · U54 · FY2017 · CA
Spatially resolved, single cell biomarkers of B cell lymphoma
$562,886Akil Merchant · Cedars-Sinai Medical Center · R01 · FY2023 · CA
Integrated Discovery Pipeline for Tumor Neoantigens
$562,825Beatriz M. Carreno · University Of Pennsylvania · R01 · FY2016 · CA
Mechanism of Immune Dysfunction and Morbid Outcomes in Response to Shock/Sepsis
$562,793Alfred Ayala · Rhode Island Hospital · R35 · FY2022 · GM
Mechanism of Immune Dysfunction and Morbid Outcomes in Response to Shock/Sepsis
$562,793Alfred Ayala · Rhode Island Hospital · R35 · FY2023 · GM
Mechanism of Immune Dysfunction and Morbid Outcomes in Response to Shock/Sepsis
$562,793Alfred Ayala · Rhode Island Hospital · R35 · FY2025 · GM